Proton Pump

Signaling Pathway Map

Research Area

Inhibitory Selectivity

Proton Pump Products

Catalog No. Information Product Use Citations Product Validations
S1354

Lansoprazole

Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.

S1389

Omeprazole

Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.

S1413

Bafilomycin A1(Baf-A1)

Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.

S1743

NEXIUM (esomeprazole magnesium)

Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.

S4075

Zinc Pyrithione

Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.

S2222

PF-3716556

PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.

S4099

Dexlansoprazole

Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.

S4845

Rabeprazole

Rabeprazole is an oral inhibitor of proton pump and blocks the production of acid by the stomach.

S5658

Omeprazole Sodium

Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.

S5502

Ilaprazole sodium

Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.

S3666

Ilaprazole

Ilaprazole is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.

S4212

Tenatoprazole

Tenatoprazole (TU-199) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.

S4665

Rabeprazole sodium

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.

S4538

Pantoprazole sodium

Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.

S2105

Pantoprazole

Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.

S5058

Revaprazan Hydrochloride

Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.

Catalog No. Information Product Use Citations Product Validations
S1354

Lansoprazole

Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.

S1389

Omeprazole

Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.

S1413

Bafilomycin A1(Baf-A1)

Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.

S1743

NEXIUM (esomeprazole magnesium)

Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.

S4075

Zinc Pyrithione

Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.

S2222

PF-3716556

PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.

S4099

Dexlansoprazole

Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.

S4845

Rabeprazole

Rabeprazole is an oral inhibitor of proton pump and blocks the production of acid by the stomach.

S5658

Omeprazole Sodium

Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.

S5502

Ilaprazole sodium

Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.

S3666

Ilaprazole

Ilaprazole is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.

S4212

Tenatoprazole

Tenatoprazole (TU-199) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.

S4665

Rabeprazole sodium

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.

S4538

Pantoprazole sodium

Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.

S2105

Pantoprazole

Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.

S5058

Revaprazan Hydrochloride

Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.

Tags: proton pump inhibition | PPI therapy | PPI medication | PPIs drugs | proton pump inhibitors medications | proton pump inhibitor drugs | PPI treatment | proton pump inhibitors list | proton pump inhibitor therapy | proton pump inhibitor treatment | proton pump inhibitors cancer | PPI prescription | proton pump inhibitor guidelines | proton pump inhibitor function | proton pump inhibitors contraindications | PPI contraindications proton pump inhibitor review